A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT05457283
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05457283 -
2023-504885-50-00 -
2021-002905-89
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05457283. Allocation not applicable; no masking; primary purpose treatment. Start 2022-11-08 (actual); primary completion 2028-08-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
- Acronym
- FIONA OLE
- Condition
- Chronic Kidney Disease
- Condition
- Proteinuria
- Condition
- Children
- Intervention (Drug)
- Finerenone (Kerendia, BAY94-8862)
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct05457283- Content hash
4bdfbd7701cd0d7195d5f115340355e48ceb5b73d93be11a27e149bcedc6e3a0